Fulcrum Therapeutics to merge with Slate Medicines in reverse merger deal
The combined company will focus on Slate's migraine pipeline and raise $245 million in a private placement to fund operations into 2029.
Fulcrum Therapeutics and Slate Medicines announced on August 17, 2026 that they have entered a definitive agreement to combine the companies in an all-stock transaction.1 The combined entity will operate under the name Slate Medicines and is expected to trade on Nasdaq under the ticker symbol "SLTE."1
The deal centers on Slate's pipeline of potentially best-in-class therapeutics, including SLTE-1009, a clinical stage subcutaneous anti-PACAP/VIP monoclonal antibody for the prevention of migraine and other headache disorders.1 The candidate was engineered with half-life extension to enable subcutaneous dosing and potential for quarterly administration.1 The program has received clearance to enter Phase 1 clinical trials in Australia, with initial pharmacokinetic and safety data anticipated mid-year 2027.1 Slate is also developing a second candidate, SLTE-2100, a bispecific antibody targeting PACAP/VIP and CGRP, currently in lead optimization and expected to enter clinical trials in the second half of 2027.1
Alongside the merger, Slate secured an oversubscribed concurrent private placement of $245 million from a syndicate led by Frazier Life Sciences, including Forbion, RA Capital Management, Deep Track Capital, Foresite Capital, OrbiMed, RTW Investments, and Mingxin Capital.1
Under the merger terms, pre-Merger Slate stockholders excluding new investors are expected to own approximately 55.9% of the combined company, the Investors approximately 39.1%, and pre-Merger Fulcrum stockholders about 5.0%, on a fully-diluted basis.1 The exchange ratio assumes a valuation for Fulcrum of $31.3 million and a valuation for Slate of $350.0 million, exclusive of the $245.0 million concurrent investment.1
Fulcrum also expects to declare a cash dividend to pre-Merger Fulcrum stockholders of $270 million in the aggregate, subject to adjustment.1 The transaction has received unanimous support from both boards and is expected to close in the fourth quarter of 2026, subject to stockholder approval, SEC registration effectiveness, and Hart-Scott-Rodino antitrust clearance.1 Termination fees apply: Fulcrum may owe Slate $10 million, and Slate may owe Fulcrum $15 million under certain circumstances.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.